Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 03, 2025, titled "Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL(200 mg/mL) Single-Dose Vials".
Press Release Mar 03 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Glenmark Pharmaceuticals Inc., USA has acquired and launched Acetylcysteine Injection in single-dose vials, as reported in the filing. The product is expected to have therapeutic effects similar to an existing drug, Acetadote, which has seen significant market sales. This acquisition is part of Glenmark's strategy to enhance its injectable portfolio in the U.S. market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Feb 27 2025
- Press Release Feb 14 2025
- Press Release Feb 12 2025
- Press Release Feb 10 2025
- Press Release Jan 21 2025
Later from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Mar 10 2025
- Press Release Mar 12 2025
- Press Release Mar 20 2025
- Glenmark Pharmaceuticals Limited Press Release Apr 01 2025
- Press Release Apr 16 2025
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals